Skip to main content

Table 2 Relative binding free energy estimates

From: Quantitative analysis of the effect of tubulin isotype expression on sensitivity of cancer cell lines to a set of novel colchicine derivatives

 

I

IIa

IIb

III

IVa

IVb

D01

-13.2 ± 1.8

5.9 ± 1.5

-2.8 ± 1.6

1.1 ± 1.7

5.5 ± 2.6

-16.9 ± 2.7

D02

-9.6 ± 3.3

-24.8 ± 1.6

-7.9 ± 2.2

1.4 ± 2.2

15.1 ± 4.0

-5.4 ± 3.9

D03

-19.9 ± 6.2

-10.7 ± 3.9

-17.0 ± 3.9

6.6 ± 2.4

-9.5 ± 4.7

-20.7 ± 7.6

D04

-30.0 ± 4.8

-8.3 ± 2.1

-7.0 ± 3.9

2.2 ± 4.0

-8.2 ± 4.2

-10.0 ± 3.4

D05

-13.8 ± 3.4

-11.5 ± 2.0

3.5 ± 2.4

5.0 ± 1.7

-7.0 ± 3.5

-13.9 ± 2.1

D06

8.6 ± 4.0

4.8 ± 2.1

20.0 ± 1.7

-4.3 ± 1.3

8.1 ± 2.6

-12.7 ± 5.7

D07

-2.8 ± 0.8

-9.8 ± 1.7

2.6 ± 1.7

1.2 ± 1.6

1.8 ± 2.3

-10.2 ± 1.9

D08

-2.5 ± 2.7

-7.8 ± 1.6

1.1 ± 4.5

2.2 ± 3.0

3.5 ± 3.1

-16.5 ± 6.2

D09

2.9 ± 5.8

-7.0 ± 1.9

0.1 ± 3.3

0.3 ± 4.4

14.1 ± 3.7

4.7 ± 6.3

D10

-10.6 ± 4.6

-13.2 ± 3.0

-4.9 ± 4.3

-21.7 ± 1.8

-15.9 ± 4.1

-15.8 ± 6.1

D11

37.6 ± 1.6

-0.6 ± 0.8

10.7 ± 1.7

13.1 ± 0.3

3.2 ± 3.4

-19.1 ± 1.6

D12

-15.6 ± 1.6

-23.2 ± 2.1

-4.1 ± 1.9

-15.1 ± 1.6

-2.8 ± 2.7

-30.4 ± 3.3

D13

0.1 ± 2.3

-5.2 ± 3.4

9.7 ± 1.5

2.3 ± 2.2

-3.7 ± 2.3

-18.1 ± 3.6

D14

-0.1 ± 4.0

-11.0 ± 1.9

0.6 ± 1.5

26.3 ± 1.9

26.5 ± 2.7

-20.0 ± 6.1

D15

12.4 ± 3.3

-3.5 ± 1.6

-1.4 ± 0.8

6.3 ± 1.6

-4.3 ± 2.3

-4.4 ± 3.2

D16

-2.8 ± 4.2

-3.9 ± 0.9

5.5 ± 1.8

-9.1 ± 3.8

-9.9 ± 3.5

-15.5 ± 2.2

D17

7.8 ± 5.1

-1.3 ± 1.4

3.1 ± 4.3

1.9 ± 1.5

26.1 ± 3.6

-6.6 ± 3.8

D18

-2.1 ± 2.9

-1.1 ± 3.4

3.3 ± 2.8

16.8 ± 1.4

-5.6 ± 1.9

-10.1 ± 2.3

D19

-10.3 ± 3.8

3.4 ± 3.2

-11.0 ± 2.3

-0.2 ± 1.5

-15.1 ± 3.2

-6.1 ± 5.1

D20

-1.7 ± 5.1

0.9 ± 1.7

10.6 ± 3.5

7.8 ± 1.8

-6.4 ± 3.9

-8.4 ± 3.7

  1. Relative binding free energy estimates of the 20 derivatives of colchicine and colchicine itself (listed in the first column) against seven tubulin isotypes listed in the top row. The energy values are given in kcal/mol and the detailed derivation is given in [36].